Soluble CD30 Measured After Lung Transplantation Does Not Predict Bronchiolitis Obliterans Syndrome in a Tacrolimus/Mycophenolate Mofetil–based Immunosuppressive Regimen

Erp, Johanna M. Kwakkel-van; Otten, Henny G.; Paantjens, Annelieke W.M.; Kessel, Diana A. van; Ginkel, Walter G.J. van; Bosch, Jules M.M. van den; Graaf, E.A. van de

doi:10.1016/j.healun.2008.06.007

Cited by 5 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This T reg hypothesis may not seem to fit with published data showing up‐regulation of sCD30 prior to BOS [14]. However, in our patient cohort we were not able to reproduce this finding and found instead unaltered sCD30 levels prior to BOS under the current immune suppressive regimen [36]. Moreover, shedding of CD30 from T regs resulting in increased serum sCD30 levels has not yet been reported.…”

Section: Discussioncontrasting

confidence: 80%

Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome

Paantjens¹,

Erp

Ginkel³

et al. 2008

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe main reason for mortality after lung transplantation is the bronchiolitis obliterans syndrome (BOS), which represents chronic rejection. As soluble CD30, which is produced mainly by activated T helper 2 (Th2) cells, was shown to be related to development of BOS, we aimed to investigate the relation between development of BOS and Th2 chemoattractant thymus and activation regulated chemokine (TARC/CCL17). In 54 patients we measured serum TARC levels prior to transplantation by enzyme-linked immunosorbent assay, and in 44 of these patients sera were analysed at months 1, 2 and 3 after lung transplantation. In addition, longitudinal measurements were performed in sera from eight healthy controls and 14 patients, the latter taken over a period of 2 years post-transplantation from seven patients developing BOS plus seven clinically matched BOS-free patients. Median serum TARC levels post-transplantation of patients who developed BOS were significantly lower than those of the matched BOS-free patients (P = 0·05). A receiver operating characteristics analysis (area under the curve 0·77), together with a Kaplan-Meyer analysis, showed that serum TARC levels below 325 pg/ml in the first month post-transplantation can predict development of BOS post-transplantation (P = 0·001). In contrast, pretransplant serum TARC levels were not significantly different between patients developing BOS, BOSfree patients or healthy controls. In conclusion, pretransplantation serum TARC levels do not predict the development of BOS post-transplantation, but measurement of the serum TARC levels in the first month directly after transplantation can provide us with a tool to identify the group at risk of developing BOS.

show abstract

Section: Discussioncontrasting

confidence: 80%

Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome

Paantjens¹,

Erp

Ginkel³

et al. 2008

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Th2 cells shed CD30 upon activation. In several studies, associations were found between circulating concentrations of soluble CD30 and BOS occurrence after lung transplantation [16][17][18][19]. In our study, no correlation was found between serum concentrations of TARC, sCD30 and expression of CCR4 on peripheral T cells in a longitudinal analysis (data not shown).…”

Section: Discussioncontrasting

confidence: 74%

Lung transplantation affects expression of the chemokine receptor type 4 on specific T cell subsets

Paantjens¹,

Graaf

Erp

et al. 2011

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryAlloreactive T cells that infiltrate the graft after lung transplantation (LTx) play a role in chronic rejection. Chemokines such as thymus and activationregulated chemokine (TARC), macrophage-derived chemokine (MDC) and monocyte chemotactic protein-1 (MCP-1) are produced locally in the lung and attract T cells via chemokine receptor 4 (CCR4). In a TARC gradient, cells expressing CCR4++ migrate more efficiently than CCR4 + -expressing cells. In this study, we compared the CCR4 expression of T cells in blood from 20 lung transplant recipients to healthy controls. We then examined whether CCR4 expression is associated with the occurrence of chronic rejection. The CCR4 ++ expression was decreased on CD4 T cells from LTx patients (P < 0·0001) when compared to healthy controls. The analysis of CD4 T cell subsets showed that this decrease was present on central memory, effector memory and terminally differentiated T cells (P = 0·0007, P < 0·0001 and P = 0·05, respectively), while a trend was found for naive CD4 T cells (P = 0·06). Also, the expression of CCR4 + on regulatory T cells (Tregs) was decreased in LTx patients when compared to healthy controls (P = 0·02). Interestingly, the CCR4 ++ expression on CD4 effector memory T cells was decreased in patients developing chronic rejection sometimes more than a year before the clinical diagnosis when compared to patients who did not (P = 0·04). The analysis of CD8 T cell subsets only showed the CCR4 + expression to be increased significantly on effector memory and terminally differentiated CD8 T cells (P = 0·02, P = 0·03, respectively) in LTx patients, but no relation was found in chronic rejection. In conclusion, the expression of CCR4 on T cell subsets was altered after LTx and appears to be related to chronic rejection.

show abstract

“…26 Similarly, in lung transplantation, post-transplant sCD30 has been proposed to predict the onset of bronchiolitis obliterans, a consequence of chronic lung allograft rejection, albeit with conflicting underpinning evidence. 27,28 In conclusion, the results of our study show that pre-transplant serum sCD30 is not a useful biomarker for predicting either acute rejection or recipient survival after heart transplantation. Further studies are needed to determine whether serial measurements of sCD30 after heart transplantation have predictive value for transplant outcome.…”

Section: Discussionmentioning

confidence: 69%

Soluble CD30 Levels in Recipients Undergoing Heart Transplantation Do Not Predict Post-transplant Outcome

Ypsilantis

Key

Bradley

et al. 2009

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Soluble CD30 Measured After Lung Transplantation Does Not Predict Bronchiolitis Obliterans Syndrome in a Tacrolimus/Mycophenolate Mofetil–based Immunosuppressive Regimen

Cited by 5 publications

References 20 publications

Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome

Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome

Lung transplantation affects expression of the chemokine receptor type 4 on specific T cell subsets

Soluble CD30 Levels in Recipients Undergoing Heart Transplantation Do Not Predict Post-transplant Outcome

Contact Info

Product

Resources

About